Medical Cannabis Access, Patient Choice and the Limits of the Evidence
State medical-cannabis programs do more than determine where cannabis can be purchased. They also determine which patients can legally seek certification—and which symptoms or diagnoses appear in the data used to evaluate those programs.
An analysis of more than 211,000 patient records by NuggMD’s 2022 Annual Cannabis Conditions Report found that restrictive qualifying-condition rules may discourage some people from pursuing medical-cannabis evaluations or lead them to report a secondary condition instead of the problem they primarily want to treat.
The findings should not be read as proof that medical cannabis is effective for every condition, or that state restrictions directly violate a legal right to treatment. Rather, they highlight how eligibility rules can shape patient choices, clinical conversations and the quality of available information.
What the NuggMD analysis found
NuggMD compiled anonymized information from patients who used its telemedicine platform. Because the sample consisted of people seeking an evaluation through a commercial service—and did not represent all medical-cannabis patients—it cannot be treated as a nationally representative survey or a clinical trial.
Still, the size of the dataset offered a useful look at the reasons patients sought certification. Chronic or severe pain was the most commonly reported reason, appearing in 26.3% of evaluations. Anxiety accounted for 18.86% of reports. The analysis also identified substantial shares of patients seeking cannabis for post-traumatic stress, stress, insomnia and other symptoms.
Many patients reported more than one condition: 63.77% selected multiple conditions during the evaluation process. Another 8.74% said they could not find their specific condition on their state’s list. NuggMD suggested that some patients may instead choose a related diagnosis or comorbidity when their primary concern is not explicitly recognized by state law.
Those patterns varied sharply by geography. Anxiety was reported much more often in the West, where it was more commonly recognized within state programs, while pain was more prominent in the Midwest and Northeast. That does not necessarily mean patients in different regions experience different illnesses. It may partly reflect what each state allows patients to report when they apply.
What the evidence says about prescription drugs
Consider a 2019 review, “Is There Less Opioid Abuse in States Where Marijuana Has Been Decriminalized, Either for Medicinal or Recreational Use?” The review examined 10 studies, including cross-sectional, retrospective and state-level ecological research.
Its conclusions were considerably more cautious than the original article suggested. Several studies associated medical-cannabis laws with lower opioid prescribing, opioid-related hospitalizations or overdose mortality. Other evidence pointed in the opposite direction: one patient-level study found greater odds of nonmedical opioid use among cannabis users, and a crude comparison of state data found higher opioid-overdose death rates in states that had legalized medical cannabis.
The review emphasized that these studies could not establish causation. State-level comparisons are especially difficult to interpret because they do not show whether the same individual substituted cannabis for an opioid. States with medical-cannabis laws may differ from other states in healthcare access, prescribing patterns, demographics, substance-use trends and the severity of the opioid crisis.
For that reason, it is not accurate to conclude that restrictive medical-cannabis laws cause patients to rely on dangerous prescription drugs, or that broader access necessarily reduces opioid-related harm. The evidence supports further study, not a simple account of cannabis as either a proven replacement for prescription medication or an established gateway to it.
Access and data are closely connected
Qualifying-condition lists influence more than who receives a medical-cannabis recommendation. They also affect what researchers see. If patients with anxiety, insomnia or another unlisted condition are required to apply under a different diagnosis, official records may overstate some conditions and hide others.
This creates a feedback problem: policymakers use patient data to assess demand and refine eligibility rules, but restrictive rules can determine which patients enter the system and how their needs are recorded in the first place.
The broader legal landscape has continued to change since the NuggMD analysis was conducted. The National Conference of State Legislatures’ overview of state medical-cannabis laws tracks differences in qualifying conditions, access rules and program structures across the country.
Medical access is not the same as medical proof
Patients may reasonably want the ability to discuss cannabis with a clinician and consider it alongside other treatments. But access policy and scientific evidence are separate questions. The Food and Drug Administration notes that it has approved specific cannabis-derived or synthetic cannabis-related medicines, while most cannabis products sold through state programs have not undergone FDA review for safety, effectiveness or quality.
That distinction matters particularly for conditions such as anxiety, chronic stress and insomnia, which appeared frequently in the NuggMD data but do not have the same level of clinical evidence as some approved cannabinoid-based treatments. Patients considering cannabis should discuss potential benefits, side effects, drug interactions and alternative therapies with a qualified healthcare professional.
The NuggMD analysis is best understood as evidence that state rules shape who seeks medical cannabis and how patients’ needs are documented. More representative patient studies, consistent reporting standards and prospective research are needed to determine which cannabis-based treatments help which patients—and whether changes in access affect prescription-drug use or other health outcomes.
